A regulatory submission from British firm Mundipharma, for the invasive candidiasis (IC) candidate rezafungin, has been accepted for review by the European Medicines Agency.
Developed by USA-based Cidara Therapeutics (Nasdaq: CDTX), the candidate is backed by positive results from the Phase III ReSTORE trial, which showed non-inferiority compared to the current standard of care, caspofungin.
There is a high level of unmet medical need in the treatment of IC, a severe, life-threatening systemic infection which particularly affects critically ill people in hospitals and those with a compromised immune system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze